Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma

Bill Wondergem1, Zhongfa Zhang, Dachuan Huang

  • 1Laboratories of Cancer Genetics, Cytogenetics, and Computational Biology, Van Andel Research Institute; Department of Urology, Spectrum Health Hospital, Grand Rapids, MI 49503, USA.

Cancer Research
|July 19, 2012
PubMed

Insights

The pituitary tumor transforming gene (PTTG1) is amplified and overexpressed in clear cell renal cell carcinoma (ccRCC), promoting tumor growth and invasion. PTTG1 may represent a novel therapeutic target for ccRCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The pituitary tumor transforming gene (PTTG1) is an oncogene involved in various cancers.
  • Clear cell renal cell carcinoma (ccRCC) is characterized by specific chromosomal abnormalities, including 5q amplifications of unclear significance.
  • PTTG1 is located in the 5q region amplified in ccRCC.

Purpose of the Study:

  • To investigate the functional role of PTTG1 in ccRCC tumorigenesis.
  • To determine the clinical significance of PTTG1 amplification and overexpression in ccRCC.
  • To identify potential therapeutic targets within the PTTG1 pathway in ccRCC.

Main Methods:

  • Analysis of PTTG1 amplification and expression in ccRCC tumor tissues.
  • Assessment of PTTG1's role in ccRCC progression using preclinical models.
  • Gene expression analysis to identify PTTG1-regulated genes and pathways.
  • Correlation of PTTG1 and ECT2 expression with clinical features and patient prognosis.

Main Results:

  • PTTG1 was found to be amplified and overexpressed in ccRCC tumors.
  • PTTG1 amplification and overexpression correlated with high tumor grade and poor patient prognosis.
  • PTTG1 ablation in preclinical models reduced ccRCC tumorigenesis and invasion.
  • PTTG1 influences the expression of ECT2, a proto-oncogene associated with invasive disease.

Conclusions:

  • PTTG1 acts as an oncogene in ccRCC, driven by amplification on chromosome 5q.
  • PTTG1 expression is linked to aggressive tumor characteristics and poor outcomes.
  • PTTG1 and its downstream target ECT2 represent potential novel therapeutic targets for ccRCC.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...